Dianthus Therapeutics (NASDAQ:DNTH) Price Target Raised to $51.00 at Raymond James

Dianthus Therapeutics (NASDAQ:DNTH) had its target price raised by Raymond James from $34.00 to $51.00 in a report published on Thursday, Benzinga reports. Raymond James currently has an outperform rating on the stock.

DNTH has been the topic of a number of other research reports. Jefferies Financial Group boosted their price objective on shares of Dianthus Therapeutics from $22.00 to $39.00 and gave the company a buy rating in a research report on Friday, March 22nd. Wedbush upped their price target on shares of Dianthus Therapeutics from $24.00 to $33.00 and gave the company an outperform rating in a report on Friday, March 22nd. Finally, Stifel Nicolaus started coverage on shares of Dianthus Therapeutics in a research note on Thursday, February 15th. They issued a buy rating and a $44.00 price objective for the company. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of Buy and an average target price of $42.40.

Dianthus Therapeutics Stock Performance

Shares of DNTH stock opened at $23.25 on Thursday. Dianthus Therapeutics has a 1 year low of $6.58 and a 1 year high of $33.77. The stock’s 50 day simple moving average is $25.81 and its two-hundred day simple moving average is $17.29.

Dianthus Therapeutics (NASDAQ:DNTH) last released its earnings results on Thursday, March 21st. The company reported ($0.71) earnings per share for the quarter, beating the consensus estimate of ($1.11) by $0.40. The company had revenue of $0.46 million for the quarter, compared to the consensus estimate of $0.73 million. As a group, sell-side analysts forecast that Dianthus Therapeutics will post -1.92 EPS for the current year.

Institutional Trading of Dianthus Therapeutics

A number of large investors have recently made changes to their positions in the stock. FMR LLC purchased a new position in Dianthus Therapeutics in the 3rd quarter worth about $28,961,000. Avidity Partners Management LP bought a new stake in shares of Dianthus Therapeutics during the third quarter valued at approximately $16,644,000. Atlas Venture Life Science Advisors LLC bought a new stake in shares of Dianthus Therapeutics during the third quarter valued at approximately $3,240,000. Vestal Point Capital LP bought a new position in Dianthus Therapeutics in the fourth quarter worth approximately $1,404,000. Finally, Vanguard Group Inc. bought a new position in Dianthus Therapeutics in the third quarter worth approximately $1,734,000. 47.53% of the stock is owned by hedge funds and other institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.